Notably, with more patients being diagnosed as FS, it became clear that the spectrum of symptoms widely differs among patients depending on the type and location of the mutation in the FOXG1 gene (Mitter et al., 2018; Vegas et al., 2018), highlighting the need for patient-specific animal models and personalized therapeutic intervention for FS patients. Here, FOXG1 is linked to Feingold syndrome.